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Abstract: Close control of blood glucose levels significantly reduces vascular 
complications in diabetes.  Heavy derivative controllers utilising the data density 
available from emerging biosensors are developed to provide tight, optimal control of 
elevated blood glucose levels.  A two-compartment human model is developed for 
intravenous infusion from physiologically verified subcutaneous infusion models to 
enable a first of its kind, proof-of-concept clinical trial.  Results show tight control with 
very similar performance to modelled behaviour and strong correlation between modelled 
insulin used versus the amounts used in clinical trials to validate the models and methods 
developed. Copyright © 2003 IFAC 
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1. INTRODUCTION 
 
Diabetes is a disorder of the metabolism whereby 
insufficient insulin is produced by the beta cells, and 
as such blood glucose cannot be transported out of 
the blood.  Lack of insulin results in blood glucose 
levels remaining dangerously high, which untreated 
over time leads to costly complications, including 
kidney failure, blindness, nerve damage, heart attack 
and stroke.  Over 120 million people are affected by 
diabetes worldwide, and this number is expected to 
rise to 300 million by the year 2025 (Thomsen et al., 
2001). 
     
 
After a meal blood glucose rises over the basal level, 
which is approximately 4.5mmol/L for a normal 
individual, and typically takes two-three hours to 
return to basal levels.  Type 1 diabetic individuals see 
high blood glucose levels which do not fall without 
exogenous insulin, while Type 2 diabetic individuals 
fall towards basal levels very slowly and may require 
exogenous insulin in severe cases.  Type 1 and Type 
2 diabetic individuals typically start with elevated 
basal blood glucose levels, as a result of their 
condition. 
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Current treatment methods involve regular point 
monitoring of the plasma glucose level and injecting 
insulin into the subcutaneous tissue as required. 
Using a glucose monitoring system and an insulin 
pump or syringe injections, all current treatments are 
performed manually.  Therefore, diabetic individuals 
must monitor food intake and daily activity to 
maintain acceptable blood glucose levels.   
 
For ease of management, many subjects elect to 
maintain strict routines and diets to minimize manual 
monitoring and injection, reducing intervention and 
difficulty.  This regime can lead to severe limitation 
of the subjects’ lifestyle and is prone to human error.  
As a result, many diabetic individuals have difficulty 
maintaining tight blood glucose control, resulting in 
regular exposure to elevated blood glucose levels.   
 
Hence, automated treatment promises better, more 
consistent control of blood glucose and an associated 
reduction in diabetes related complications.  Existing 
insulin pumps, and emerging non-invasive and semi-
invasive glucose monitoring systems may be easily 
interconnected to realise a closed loop system.  
Ultimately, the control unit should be able to 
automate 90 – 95% of a diabetic’s day-to-day insulin 
care, freeing the patient from the anxieties and stress 
of constantly monitoring their blood glucose system 
behaviour, allowing them to lead more “normal” 
lives.  Therefore, the goal is to control the essential 
dynamics rather than all of the dynamics and 
exceptional behaviours. 
     
 
Years of research on modelling and managing 
diabetes have led to no shortage of theoretical 
automated solutions (e.g. Ollerton, 1989; Kienetz and 
Yoneyama, 1993; Fisher, 1991; Furler et al, 1985).  
However, due to either the complexity of the 
proposed implementation, models that are not 
physiologically verified, or lack of required data 
these solutions have not been trialled. Several 
researchers have examined the analysis and 
automation of insulin administration as reviewed by 
Lehman and Deutsch (1996). In each case, the focus 
has been on controlling absolute blood glucose 
excursion rather than the shape of the glucose curve 
as with heavy derivative control (Chase et al, 2002).  
 
Prior work in tightly controlling elevated blood 
glucose levels using heavy derivative control 
employed a physiologically verified three 
compartment model based on the work of Bergman et 
al (1985).  Performance was shown to improve with 
decreased sensor lag and sampling period and the 
controlled solution outperformed the normal human 
body at a sample period of 1 minute (Lam et al, 
2002). The primary feature of derivative weighted 
control is the focus on controlling the shape of the 
blood glucose curve rather than the absolute 
magnitude of blood glucose. This approach adds 
robustness because it can account for varying rates of 
glucose absorption and other patient specific 
behaviours, as well as some other modelling errors. 
 
The research presented here develops this heavy 
derivative control approach to a proof-of-concept 
clinical trial with Intensive Care Unit (ICU) patients.  
This clinical trial is the first of its kind, to the best of 
the authors’ knowledge, to test a feedback control 
algorithm for tight glucose regulation.  The 3-
compartment model is adapted to a 2-compartment 
model for testing ICU patients who receive the 
insulin intravenously. Results are compared to 
predicted values to verify the modelling methods and 
overall approach to controlling blood glucose. 
 
 
2. CLINICAL TRIAL METHOD 
 
 
The proof-of-concept clinical trials conducted 
effectively simulate a true feedback control system 
with a 15-minute sampling period, which works well 
and represents a realistic level of system performance 
(Chase et al, 2002; Lam et al, 2002).  They are 
designed specifically to test the effectiveness of the 
heavy derivative control methods and to verify the 
simulations and design that led to them.  The trials 
are conducted on ICU patients since they represent a 
highly controlled test group who often experience 
elevated blood glucose levels.  Additionally, tight 
glucose control has been shown to reduce ICU 
patient mortality by as much as 45%, which is an 
added benefit of tight glucose regulation for this 
subject group (Van den Berghe et al, 2001).    
 
Qualifying patients had to be stable, have elevated 
blood glucose levels over 8 mmol/L, have an arterial 
line and a nasogastric feed, and be expected to remain 
in the ICU for at least three days. In addition, patients 
with morbid obesity (BMI > 35kg/m2) or 
neuromuscular blockade were not considered. The 
Canterbury Ethics Committee granted ethics approval 
for these trials. 
 
The clinical trials are a two-day procedure for each 
participant.  The first day of the trial measures the 
uncontrolled glucose regulatory system response and 
the second day implements active insulin control of 
the glucose regulatory system response using the 
heavy derivative control algorithm. 
 
 
2.1 Clinical Trial Day One: 
 
The trial begins at 0700 hours at which time the 
patient is fasted for four hours.  Blood glucose 
readings are taken every hour to determine a basal 
blood glucose level.  At 1100 hours, blood is taken 
for C-peptide and blood insulin tests to screen for 
insulin contamination and determine the basal insulin 
level, respectively. The patient is then given a 75g 
oral glucose tolerance test (OGTT) glucose dose via 
the nasogastric tube. Plasma glucose is measured at 
15-minute intervals until 1500 hours.  Paired samples 
are taken, with one analysed using a bedside 
GlucocardTM Test Strip 2 glucose testing kit and the 
other sent to the laboratory for comparison.  The error 
in the absolute readings are approximately 7% for the 
GlucocardTM Test Strip 2 tests, and 3% for the 
laboratory tests at typical elevated blood glucose 
levels (Phillips et al, 1994; Peters et al, 1996). 
 
 
2.2 Clinical Trial Day Two: 
 
The procedure is repeated as per day one, however 
short acting soluble insulin with 0.2U/ml in 0.9% 
saline is infused via an intravenous cannula using a 
Graseby 3500 syringe pump.  Plasma glucose is 
measured at 15-minute intervals as previously and the 
insulin infusion rate is manually adjusted every 15 
minutes according to the heavy derivative control 
algorithm. This approach is designed to specifically 
test the algorithm and eliminate the impact of any 
specific equipment.   
 
 
3.  MATHEMATICAL MODELLING 
 
To implement tight glucose control using an 
automated insulin infusion system for patients in an 
intensive care unit (ICU) requires a model of the 
glucose regulatory system that accounts for 
intravenous infusion of exogenous insulin. The initial 
physiologically verified model employed originated 
from the work of Bergman et al. (1985), utilizing the 
concept of a remote compartment for the transport of 
     
insulin between the subcutaneous infusion site and its 
utilization to reduce blood glucose levels.   
 
Intensive care unit (ICU) patients have direct 
arterial/venous lines that bypass the subcutaneous 
compartment in the three compartment model, and 
require only two compartments. The first 
compartment models insulin uptake into the blood, 
and the second models blood glucose level and 
insulin mediated transport of glucose from the blood.  
The model is defined:  
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Where G is the blood glucose level over basal level 
GB, I is the insulin level over basal level IB, u(t) is the 
exogenous insulin infusion, P(t) is the exogenous 
glucose input, n is a time constant for the insulin, and 
p1 and  p4 are patient dependant parameters. 
Currently, p4 is a time constant that couples the blood 
insulin level to the rate of glucose utilization by the 
body, representing the simplest possible dynamic 
between these two compartments.   
 
Additional model dynamics linking the two 
compartments in Equations (1) and (2) may be 
needed, however, any missing dynamics are small 
enough to have negligible effect on the ability to 
derive an appropriate controller. More specifically, 
the upward rise of glucose concentration in the blood 
in this model does not depend on p4, and it is this rise 
that the heavy derivative control focuses on limiting. 
  
The model is therefore patient specific and is adapted 
to each person before a controller is developed. In the 
longer term, average parameter sets will be identified 
from extended clinical trials that are in development. 
Such parameters, if they can be identified for 
different types of patient would eliminate a great deal 
of customisation.  
 
Hence, current controller design is accomplished in 
three steps. First data from an uncontrolled oral 
glucose tolerance test (OGTT) is gathered from the 
patient. Secondly, the patient specific parameters,  p1 
and p4, are obtained using unconstrained optimisation 
designed to minimise the difference between 
modelled and test behaviour. Finally, given a model 
that fits the error bounds of the uncontrolled patient 
data, control gains are developed using a second 
unconstrained optimisation to find derivative 
weighted gains that minimise the magnitude and 
duration of blood glucose excursion from the 
patient's basal level for the same OGTT input. 
 
The first step in the process is to fit a continuous 
function to the patient's uncontrolled, day one, OGTT 
data using a log-normal function, which tends to 
match such data quite well [8], to derive a function, 
Gpatient, which can be discretised for optimisation into 
a series of time points, patientG .  Changing the values 
of p1 and p4 will change the model output, so that a 
similar series, elGmod , matches the continuous 
function approximated by patientG . Unconstrained 
optimisation can accomplish this error minimisation 
task using an objective function defined: 
            
 (3) 
 
Where C is a large positive constant, defined to 
ensure that p1 and p4 remain positive and therefore 
valid as parameters in the model. By changing the 
discretisation, certain points in the model solution 
and the continuous function Gpatient can be constrained 
to match more accurately. Typically, several extra 
time points around the peak of the glucose response 
curve are added to ensure the rise and inflection of 
the glucose curve are adequately captured. It is this 
rise and inflection that are critical to effective 
derivative weighted control, as it is this portion of the 
curve that instigates the vast majority of the control, 
and hence insulin, infusion input. 
 
The total amount of glucose infused simulating an 
OGTT is 34 mmol/L, a value obtained by converting 
75g of glucose and assuming the patient has the 
glucose evenly distributed in a 12L fluid volume 
(Furler et al, 1985; Bergman et al, 1985). To account 
for the different rates of uptake, the peak of the 
simulated exogenous glucose infusion profile, P(t), is 
set at approximately 80% of the time required for the 
patient’s uncontrolled OGTT peak glucose reading, 
and modelled as a continuous lognormal function. 
Hence, the simulated and actual uptake rates for 
uncontrolled OGTT will be similar and the total 
glucose input will be identical.   
 
The controller determines the amount of exogenous 
insulin, u(t), infused. The model is set to run with a 
15 minute sampling interval to match the clinical trial 
program developed. A heavy derivative proportional-
derivative (PD) controller is employed:  
 
u(t) = U0 * ( 1 + Kp*(G+Gprime) + 
Kd*dG/dt ) 
(4) 
tbprime GGG −=  (5) 
 
Where U0 is the basal insulin infusion rate, Kp is the 
proportional gain and Kd the much larger derivative 
gain (Lam et al, 2002). More specifically, the 
proportional gain is typically 20-50x smaller than the 
derivative gain. Gprime is an offset term to the 
proportional control.  A patient with a high basal 
glucose level, Gb, can have their glucose level 
controlled to a lower target blood glucose level, Gt, 
by increasing Gprime, which is the difference between 
the target blood glucose level (Gt) and the actual, 
elevated basal blood glucose level (Gb) for the 
patient. The more positive Gprime is the greater the 
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proportional feedback term by setting the target basal 
level below the actual (elevated) basal level.  
 
The control gains are determined by minimising the 
objective function (R) defined: 
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where C1, C2 and C are positive constants that can be 
suitably modified to obtain the desired results.  The 
G( t~ ) terms in the objective function minimise the 
area between the blood glucose levels, G( t~ ), from 
the measured data and the target blood glucose 
levels, Gt. The )~(tG& terms in the objective function 
minimise the slope of the output glucose levels, 
reducing oscillation in the blood glucose response 
curve, a problem that can occur if the gains are too 
large. The exponential terms in the objective function 
ensure Kd and Kp are positive, providing the basis for 
a practicable solution. Overall, optimisation is 
employed not to find a best solution but to efficiently 
search a large domain of possible control gains.  
 
 
4.  CLINICAL RESULTS 
 
Initial proof of concept clinical trials were performed 
on two ICU patients.  Following consent being 
obtained, each patient was subjected to the two day 
trial defined.  While initial patients are tested with 
patient specific models, later patients will employ 
average parameters based on extended trials being 
developed. 
 
Patient 1 was a 67 year old female subject in the ICU 
for three days suffering from kidney failure.  The 
kidneys can remove up to 30% of effective insulin, so 
kidney failure is an “insulin sparing” condition that 
can lead to a flatter glucose response (Charpentier et 
al, 2000). The patient's basal insulin level of 70 
pmol/L was slightly high and the patient was 
therefore both hyperglycaemic and somewhat hyper-
insulinaemic as well.  
 
Figure 1 shows the measured and model predicted 
glucose response for day one (uncontrolled) and day 
two (controlled).  The measured data is presented 
with the 7% error associated with GlucoCard™ 2 
measurements.  The magnitude and duration of blood 
glucose excursion from the basal level are reduced by 
at least 50%. The target sub-basal glucose level of 
5.5mmol/L was not fully reached, as the derivative 
control was not effective as the tail of the glucose 
response curve flattens off. This failure is an example 
of the need for gain scheduling or a modified control 
approach in this flatter response regime. Note also 
that the uncontrolled response is relatively flat for an 
OGTT, which is a result of the patient's relative 
hyper-insulinaemia resulting, at least in part, from 
kidney failure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: Patient 1 OGTT Response 
 
Overall, the automated algorithm provided rapid, 
effective control of the OGTT input and the 
simulated controlled response was an extremely good 
match for the measured data, as seen in Figure 1. The 
difference in day one and day two basal levels is 
primarily due to changes in feeding and insulin 
administration over the night between the OGTTs.  
Finally, the patient’s blood glucose concentration 
began to increase steadily back to 10 mmol/L after 
the controlled day two test when hospital staff 
returned to their sliding scale protocol showing the 
need for, and effectiveness of, automated methods 
for tight glucose regulation.   
 
Patient 2 was a 75 year old male in the ICU for 2 
days suffering from a significant head injury.  
Uncontrolled patient data from day one, as shown in 
Figure 2, showed the patient behaves as a Type 1 
diabetic. The extremely high glucose levels and 
almost permanent period of excursion from the basal 
glucose level are similar to a Type 1 diabetic OGTT 
response, however available records did not show 
such a diagnosis. Laboratory tests for insulin level 
confirmed the assumption of essentially Type 1 
diabetic behaviour with a very low insulin level of 
3pmol/L.    
 
The controlled response in Figure 2 shows the need 
for an additional insulin accumulation dynamic in the 
model, with the dip in glucose response at 180 
minutes.  The controlled simulation does not capture 
this dip, or the initial stronger rise, illustrating how 
the simple coupling dynamic in Equation (1), 
utilizing the parameter p4 is not fully adequate. The 
actual results indicate that some insulin input 
accumulates in a second compartment before 
utilization.  
 
Approximating this dynamic by adding a 75 minute 
delay on a portion of the insulin infusion resulted in a 
curve more closely aligned with the controlled patient 
data in Figure 2. This approximation delays the onset 
of some of the infused insulin much as an 
     
accumulation in a secondary compartment would. 
The results confirm the need for this accumulator 
dynamic. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: Patient 2 OGTT Response 
 
The overall performance of the controller was still 
quite effective. The peak blood glucose excursion is 
reduced 60% and the duration was cut to two hours 
from the much greater than four hour excursion that 
would have resulted in the uncontrolled case. Finally, 
the eventual final basal level was reduced 
approximately 3mmol/L from the starting value for 
that day. 
 
Comparisons between the predicted and actual 
insulin infusion profiles for day two of the trials were 
made as a means for determining the effectiveness of 
the modelling methods.  Table 1 shows that the total 
insulin infused differed from the predicted total by no 
more than 8%.  One cause for difference is the 0.2 
U/mmol discrete insulin infusion step available 
versus the exact analog values used in the simulation, 
and a tendency to round down to the nearest discrete 
infusion level during the trials as a conservative 
choice.  The excellent match between predicted, or 
simulated, insulin usage and the actual insulin 
employed verifies the physiological accuracy of the 
models and methods employed. 
 
 
Table 1: Comparison between predicted insulin and 
trial insulin infused 
  
Blood glucose excursion and control efficacy may be 
best measured by comparing the area reduction in the 
glucose response curve and change in basal glucose 
value, as shown in Figure 3. The ratio of the two 
areas in the figure is a measure of how much the 
glucose excursion is reduced, while basal level 
reduction shows the effectiveness in reducing 
elevated levels. Table 2 summarises these values for 
both patients, with reductions of around 80% blood 
glucose excursion in area and 15-19% in basal level, 
versus the uncontrolled case.   
 
 
 
 
 
 
 
 
 
 
 
Fig. 3: Measures of Blood Glucose Excursion  
 
 
Table 2: Comparison of Glucose Excursion Data 
 
Day One  Day Two         Ratios  
  Gb  
 
A1  A2  
Gb 
Final 
Gb 
Ratio 
 
A2/A1 
1 9.6 292 60 6.1 0.85 0.21 
2 13.1 1082 196 7.9 0.71 0.18 
 
Finally, the accumulator dynamic noted in the clinical 
results has three potential causes. First, is the 
physiological battle between the body's desire to 
return to the (elevated) basal level and the controller's 
attempts to hold it down, as best seen in Figure 1. 
Second, is the demand for insulin in the blood is 
secondary to those of the brain and liver, leading to 
the possibility that meeting these demands first 
causes a reduction in useful insulin in the blood and a 
later over reaction. Finally, it is believed that insulo-
penic, or very low insulin level, patients can develop 
lipo-toxicity, suppressing insulin release from any 
active beta cells. Therefore, when exogenous insulin 
is infused these beta cells are free to release 
endogenous insulin not initially accounted for (Del 
Prato et al, 2002). Further tests will help clarify the 
specific causes of this dynamic, and improve the 
models and clinical trial methods employed. 
 
 
5.  CONCLUSIONS 
 
These trials, are to the best of the authors' knowledge, 
the first human clinical trials of feedback controlled 
active insulin infusion and have been completed with 
very good success. The research has succeeded in the 
creation and validation of an intravenous insulin 
infusion model, and in demonstrating tight actively 
controlled blood glucose level regulation for the first 
time. The heavy derivative control approach 
employed has been demonstrated to be as highly 
effective in practice as in simulation, with reduction 
in glucose excursion of up to 82% and basal glucose 
reduction of up to 19%.  
The two trials have shown a high level of correlation 
between the simulation model and the patient results.  
Patient 
Predicted 
Insulin 
(Units) 
Actual  
Insulin  
(Units) 
Difference 
(%) 
1 4.50 4.43 - 1.55 
2 4.90 4.50 - 8.16 
Time
Blood 
Glucose 
Level 
over 
Basal 
A1
A2 Gb
Gb(final)
     
This strong correlation certifies the physiological 
validity of the models and methods employed. In 
particular, the model's ability to capture the insulin 
usage to within 10% of actual values validates the 
fundamental assumptions made. However, the results 
have clearly demonstrated the need for additional 
accumulation dynamics in the intravenous glucose 
regulatory system model, and the need for gain 
scheduling or a two-stage controller to bring glucose 
levels back to a set basal value as derivative values 
become negligible in the tail of the OGTT response.  
 
Finally, two simple measures for capturing the 
effectiveness of automated glucose regulation are 
introduced. The comparison of blood glucose 
excursion area, for a given input, is seen to capture 
the essential details of the magnitude and duration of 
the blood glucose excursion from the patient's basal 
level. Secondly, many diabetic individuals have 
elevated basal blood glucose levels so that comparing 
the final basal value that the controller achieves is a 
simple measure of the controller's ability to "fight 
physiology" and reduce blood glucose below the 
basal level. 
 
Future developments include advancements in patient 
simulation models and improvements in the control 
systems employed. Particular areas of work include 
improved optimisation methods for determining 
patient specific parameters and control gains, and 
further trials on ambulatory patients using 
subcutaneous insulin infusion. The ultimate goal is 
consistent, robust automated blood glucose control. 
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